A phase 1/2 study of intravesical MK-3120 in participants with Bacillus Calmette-Guérin (BCG)-Naive or BCG-exposed high-risk non–muscle invasive bladder cancer

A phase 1/2 study of intravesical MK-3120 in participants with Bacillus Calmette-Guérin (BCG)-Naive or BCG-exposed high-risk non–muscle invasive bladder cancer

Sunday, May 17, 2026 10:04 AM to 10:12 AM · 8 min. (America/New_York)
Hall B, The Square, Learning Lab
Detail
Oncology: Bladder

Registered attendees

Scott Flanders
Scott Flanders
VP of Medical AffairsImmunityBio, Inc.
Seth Lerner
Seth Lerner
Vice Chair for Faculty AffairsBaylor College of Medicine Scott Department of Urology
Yakov Klugman
Yakov Klugman
Medical StudentRoswell Park Comprehensive Cancer Center

Log in

See all the content and easy-to-use features by logging in or registering!